The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol

被引:202
|
作者
Piper, Derek E.
Jackson, Simon
Liu, Qiang
Romanow, William G.
Shetterly, Susan
Thibault, Stephen T.
Shan, Bei
Walker, Nigel P. C. [1 ]
机构
[1] Amgen Inc, Dept Mol Struct, 1120 Vet Blvd, San Francisco, CA 94080 USA
[2] Amgen Inc, Dept Metab Disorders, San Francisco, CA 94080 USA
[3] Amgen Inc, Dept Prot Sci, San Francisco, CA 94080 USA
关键词
D O I
10.1016/j.str.2007.04.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 50 条
  • [21] PCSK9 antibody reduces LDL cholesterol
    Sarah Crunkhorn
    [J]. Nature Reviews Drug Discovery, 2012, 11 : 11 - 11
  • [22] Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
    Schmidt, Amand F.
    Holmes, Michael V.
    Preiss, David
    Swerdlow, Daniel I.
    Denaxas, Spiros
    Fatemifar, Ghazaleh
    Faraway, Rupert
    Finan, Chris
    Valentine, Dennis
    Fairhurst-Hunter, Zammy
    Hartwig, Fernando Pires
    Horta, Bernardo Lessa
    Hypponen, Elina
    Power, Christine
    Moldovan, Max
    van Iperen, Erik
    Hovingh, Kees
    Demuth, Ilja
    Norman, Kristina
    Steinhagen-Thiessen, Elisabeth
    Demuth, Juri
    Bertram, Lars
    Lill, Christina M.
    Coassin, Stefan
    Willeit, Johann
    Kiechl, Stefan
    Willeit, Karin
    Mason, Dan
    Wright, John
    Morris, Richard
    Wanamethee, Goya
    Whincup, Peter
    Ben-Shlomo, Yoav
    McLachlan, Stela
    Price, Jackie F.
    Kivimaki, Mika
    Welch, Catherine
    Sanchez-Galvez, Adelaida
    Marques-Vidal, Pedro
    Nicolaides, Andrew
    Panayiotou, Andrie G.
    Onland-Moret, N. Charlotte
    van der Schouw, Yvonne T.
    Matullo, Giuseppe
    Fiorito, Giovanni
    Guarrera, Simonetta
    Sacerdote, Carlotta
    Wareham, Nicholas J.
    Langenberg, Claudia
    Scott, Robert A.
    [J]. BMC CARDIOVASCULAR DISORDERS, 2019, 19 (01)
  • [23] LDL-CHOLESTEROL REDUCTION WITH PCSK9 INHIBITORS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
    Casula, Manuela
    Scotti, Lorenza
    Bernocchi, Ottavia
    Galimberti, Federica
    Tragni, Elena
    Corrao, Giovanni
    Catapano, Alberico Luigi
    [J]. ATHEROSCLEROSIS, 2017, 263 : E244 - E244
  • [24] The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population
    Yue, P
    Averna, M
    Lin, XB
    Schonfeld, G
    [J]. HUMAN MUTATION, 2006, 27 (05) : 460 - 466
  • [25] Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
    Amand F. Schmidt
    Michael V. Holmes
    David Preiss
    Daniel I. Swerdlow
    Spiros Denaxas
    Ghazaleh Fatemifar
    Rupert Faraway
    Chris Finan
    Dennis Valentine
    Zammy Fairhurst-Hunter
    Fernando Pires Hartwig
    Bernardo Lessa Horta
    Elina Hypponen
    Christine Power
    Max Moldovan
    Erik van Iperen
    Kees Hovingh
    Ilja Demuth
    Kristina Norman
    Elisabeth Steinhagen-Thiessen
    Juri Demuth
    Lars Bertram
    Christina M. Lill
    Stefan Coassin
    Johann Willeit
    Stefan Kiechl
    Karin Willeit
    Dan Mason
    John Wright
    Richard Morris
    Goya Wanamethee
    Peter Whincup
    Yoav Ben-Shlomo
    Stela McLachlan
    Jackie F. Price
    Mika Kivimaki
    Catherine Welch
    Adelaida Sanchez-Galvez
    Pedro Marques-Vidal
    Andrew Nicolaides
    Andrie G. Panayiotou
    N. Charlotte Onland-Moret
    Yvonne T. van der Schouw
    Giuseppe Matullo
    Giovanni Fiorito
    Simonetta Guarrera
    Carlotta Sacerdote
    Nicholas J. Wareham
    Claudia Langenberg
    Robert A. Scott
    [J]. BMC Cardiovascular Disorders, 19
  • [26] Chasing LDL cholesterol to the bottom — PCSK9 in perspective
    Peter Libby
    Lale Tokgözoğlu
    [J]. Nature Cardiovascular Research, 2022, 1 : 554 - 561
  • [27] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Stein, Evan A.
    Mellis, Scott
    Yancopoulos, George D.
    Stahl, Neil
    Logan, Douglas
    Smith, William B.
    Lisbon, Eleanor
    Gutierrez, Maria
    Webb, Cheryle
    Wu, Richard
    Du, Yunling
    Kranz, Therese
    Gasparino, Evelyn
    Swergold, Gary D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (12): : 1108 - 1118
  • [28] PCSK9 MUTATIONS: EFFECTS BEYOND LDL CHOLESTEROL
    Zampoleri, V.
    Casula, M.
    Gazzotti, M.
    Baragetti, A.
    Pellegatta, F.
    Grigore, L.
    Catapano, A. L.
    [J]. ATHEROSCLEROSIS, 2019, 287 : E195 - E196
  • [29] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Banerjee, Yajnavalka
    Shah, Karna
    Al-Rasadi, Khalid
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25): : 2425 - 2426
  • [30] Beyond LDL Cholesterol, a New Role for PCSK9
    Akram, Omar N.
    Bernier, Adeline
    Petrides, Francine
    Wong, Gida
    Lambert, Gilles
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (07) : 1279 - 1281